Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Antimicrob Agents Chemother ; 68(7): e0042024, 2024 Jul 09.
Article in English | MEDLINE | ID: mdl-38780261

ABSTRACT

Capsid assembly mediated by hepatitis B virus (HBV) core protein (HBc) is an essential part of the HBV replication cycle, which is the target for different classes of capsid assembly modulators (CAMs). While both CAM-A ("aberrant") and CAM-E ("empty") disrupt nucleocapsid assembly and reduce extracellular HBV DNA, CAM-As can also reduce extracellular HBV surface antigen (HBsAg) by triggering apoptosis of HBV-infected cells in preclinical mouse models. However, there have not been substantial HBsAg declines in chronic hepatitis B (CHB) patients treated with CAM-As to date. To investigate this disconnect, we characterized the antiviral activity of tool CAM compounds in HBV-infected primary human hepatocytes (PHHs), as well as in HBV-infected human liver chimeric mice and mice transduced with adeno-associated virus-HBV. Mechanistic studies in HBV-infected PHH revealed that CAM-A, but not CAM-E, induced a dose-dependent aggregation of HBc in the nucleus which is negatively regulated by the ubiquitin-binding protein p62. We confirmed that CAM-A, but not CAM-E, induced HBc-positive cell death in both mouse models via induction of apoptotic and inflammatory pathways and demonstrated that the degree of HBV-positive cell loss was positively correlated with intrahepatic HBc levels. Importantly, we determined that there is a significantly lower level of HBc per hepatocyte in CHB patient liver biopsies than in either of the HBV mouse models. Taken together, these data confirm that CAM-As have a unique secondary mechanism with the potential to kill HBc-positive hepatocytes. However, this secondary mechanism appears to require higher intrahepatic HBc levels than is typically observed in CHB patients, thereby limiting the therapeutic potential.


Subject(s)
Hepatitis B virus , Hepatitis B, Chronic , Hepatocytes , Humans , Hepatocytes/virology , Hepatocytes/drug effects , Animals , Hepatitis B virus/drug effects , Hepatitis B virus/physiology , Mice , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/virology , Viral Core Proteins/metabolism , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Hepatitis B Core Antigens/metabolism , Capsid/metabolism , Capsid/drug effects , Liver/virology , Liver/drug effects , Liver/metabolism , Hepatitis B Surface Antigens/metabolism , Virus Assembly/drug effects , Apoptosis/drug effects , Virus Replication/drug effects
2.
Nature ; 557(7704): 190-195, 2018 05.
Article in English | MEDLINE | ID: mdl-29695869

ABSTRACT

The enzyme telomerase adds telomeric repeats to chromosome ends to balance the loss of telomeres during genome replication. Telomerase regulation has been implicated in cancer, other human diseases, and ageing, but progress towards clinical manipulation of telomerase has been hampered by the lack of structural data. Here we present the cryo-electron microscopy structure of the substrate-bound human telomerase holoenzyme at subnanometre resolution, showing two flexibly RNA-tethered lobes: the catalytic core with telomerase reverse transcriptase (TERT) and conserved motifs of telomerase RNA (hTR), and an H/ACA ribonucleoprotein (RNP). In the catalytic core, RNA encircles TERT, adopting a well-ordered tertiary structure with surprisingly limited protein-RNA interactions. The H/ACA RNP lobe comprises two sets of heterotetrameric H/ACA proteins and one Cajal body protein, TCAB1, representing a pioneering structure of a large eukaryotic family of ribosome and spliceosome biogenesis factors. Our findings provide a structural framework for understanding human telomerase disease mutations and represent an important step towards telomerase-related clinical therapeutics.


Subject(s)
Cryoelectron Microscopy , Telomerase/metabolism , Telomerase/ultrastructure , Catalytic Domain , Holoenzymes/chemistry , Holoenzymes/genetics , Holoenzymes/metabolism , Holoenzymes/ultrastructure , Humans , Models, Molecular , Molecular Chaperones , Mutation , Protein Domains , RNA/chemistry , RNA/metabolism , RNA/ultrastructure , Ribonucleoproteins/chemistry , Ribonucleoproteins/genetics , Ribonucleoproteins/metabolism , Ribonucleoproteins/ultrastructure , Substrate Specificity , Telomerase/chemistry , Telomerase/genetics
3.
EMBO J ; 36(13): 1908-1927, 2017 07 03.
Article in English | MEDLINE | ID: mdl-28495680

ABSTRACT

The reverse transcriptase telomerase adds telomeric repeats to chromosome ends. Purified human telomerase catalyzes processive repeat synthesis, which could restore the full ~100 nucleotides of (T2AG3)n lost from replicated chromosome ends as a single elongation event. Processivity inhibition is proposed to be a basis of human disease, but the impacts of different levels of processivity on telomere maintenance have not been examined. Here, we delineate side chains in the telomerase active-site cavity important for repeat addition processivity, determine how they contribute to duplex and single-stranded DNA handling, and test the cellular consequences of partial or complete loss of repeat addition processivity for telomere maintenance. Biochemical findings oblige a new model for DNA and RNA handling dynamics in processive repeat synthesis. Biological analyses implicate repeat addition processivity as essential for telomerase function. However, telomeres can be maintained by telomerases with lower than wild-type processivity. Furthermore, telomerases with low processivity dramatically elongate telomeres when overexpressed. These studies reveal distinct consequences of changes in telomerase repeat addition processivity and expression level on telomere elongation and length maintenance.


Subject(s)
Chromosomes, Human/metabolism , Repetitive Sequences, Nucleic Acid , Telomerase/metabolism , Catalytic Domain , Humans , Models, Biological , Models, Molecular , Telomerase/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL